Neuron-specific enolase and lung cancer

Area of Science:

• Oncology
• Pulmonology
• Biomarker Research

Background:

• Neuron-specific enolase (NSE) is a known marker, often elevated in small cell lung cancer (SCLC).
• Its diagnostic utility in serum and bronchoalveolar lavage fluid (BALF) for various lung conditions, including non-small cell lung cancer (NSCLC) and COPD, requires clarification.

Purpose of the Study:

• To investigate the diagnostic validity of NSE levels in both serum (S-NSE) and BALF (B-NSE) for lung cancer.
• To compare NSE levels across lung cancer patients, COPD patients, and healthy controls.

Main Methods:

• A prospective case-control study analyzed S-NSE and B-NSE levels in 15 controls, 15 COPD patients, and 35 lung cancer patients.
• Statistical analysis was performed to compare NSE levels between groups and subgroups (e.g., smokers, cancer stages, SCLC vs. NSCLC).

Main Results:

• No significant differences in S-NSE or B-NSE levels were found between the control, COPD, and lung cancer groups.
• NSE levels did not differ significantly based on smoking status, cancer type (SCLC vs. NSCLC), or stage (I-II vs. III-IV).
• S-NSE and B-NSE were highly correlated (r = 0.84), with S-NSE showing 60% sensitivity and 40% specificity for lung cancer.

Conclusions:

• NSE can be elevated in NSCLC and COPD, not just SCLC.
• Due to the strong correlation between S-NSE and B-NSE, serum measurement is simpler and less invasive, potentially sufficing.
• NSE lacks definitive diagnostic value for lung cancer and is best suited for research settings.